ArticleInfection and drug resistance2026
Bronchoalveolar Lavage Fluid α Amylase Level a Promising Biomarker of Aspiration Syndrome: A Pilot Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Aspiration syndrome is a common respiratory disease in clinical practice. We hypothesized that bronchoalveolar lavage fluid (BALF) α-amylase might be a diagnostic biomarker for aspiration syndrome. Methods: This pilot, multicenter prospective study reviewed consenting adults who underwent clinically-indicated bronchoscopy at six hospitals. BALF samples were obtained using standardized methods. Amylase levels were measured in clinical biochemical laboratory. Aspiration syndrome was clinically diagnosed based on the Expert Task Force on Diagnosis And Treatment of Aspiration Pneumonia in Adults in China (2022) and the guidelines of the Japanese Respiratory Society. Results: Among 248 participants, 159 met clinical criteria for aspiration. The median level of BALF α-amylase in cases was significantly higher than that in controls (2884.2 IU/L vs 30.0 IU/L, Conclusion: BALF α-amylase might be a promising biomarker for distinguishing aspiration syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.